BridgeBio Pharma (BBIO) Change in Account Payables (2018 - 2026)

BridgeBio Pharma has disclosed Change in Account Payables across 9 years of filings, most recently posting -$7.2 million for Q1 2026.

• Change in Account Payables for Q1 2026 came in at -$7.2 million, down 140.81% year-over-year; the trailing twelve-month figure through Mar 2026 was $1.9 million (down 92.53% YoY), and the FY2025 annual result was $26.6 million, up 1659.85% from the prior year.
• Change in Account Payables came in at -$7.2 million for Q1 2026 at BridgeBio Pharma, down from $17.5 million in the prior quarter.
• In the past five years, Change in Account Payables ranged from a high of $17.6 million in Q1 2025 to a low of -$7.4 million in Q3 2025.
• The 5-year median for Change in Account Payables is -$1.1 million (2025), against an average of $1.4 million.
• Peak annual rise in Change in Account Payables reached 5061.41% in 2024, while the deepest fall reached 618.88% in 2024.
• BridgeBio Pharma's Change in Account Payables stood at $1.4 million in 2022, then soared by 349.42% to $6.2 million in 2023, then tumbled by 160.56% to -$3.7 million in 2024, then soared by 567.96% to $17.5 million in 2025, then sank by 140.91% to -$7.2 million in 2026.
• The last three Change in Account Payables figures came in at -$7.2 million (Q1 2026), $17.5 million (Q4 2025), and -$7.4 million (Q3 2025), per Business Quant data.